Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus MESTINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus MESTINON.
ADLARITY vs MESTINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor